Pemafibrate

Pemafibrate, sold under the brand namd Parmodia, is a peroxisome proliferator-activated receptor alpha (PPARα) agonist. It is developed and marketed by Kowa Pharmaceuticals.

In July 2017, Pharmaceuticals and Medical Devices Agency approved it in Japan.